• Home
• Meetings
• Previous Meetings
• 2024
• EHA-SfPM Precision Medicine Meeting
• Meeting Program

Meeting Program

EHA-SfPM Precision Medicine

Day 1 - Wednesday, September 25

	Vandsalen	Ballonsalen	Blomstersalen
13:30 - 13:45	Opening & Welcome
	Krister Wennerberg
13:45 - 14:30	Keynote: Loading the gun; how agnostic mechanistic studies can inform Precision Medicine
	Introduction: Krister Wennerberg
	Brian Huntly
14:30 - 14:45	Coffee break (Foyer)
14:45 - 16:45	Session 1: Precision medicine trials
	Chair: Keith Flaherty
	• EXALT1 and 2 trials - Philipp Staber • NCI-MATCH: the end of an era in precision medicine or just the start? - Keith Flaherty • Functional precision oncology for guiding treatment of patients with metastatic colorectal cancer - Kushtrim Kryeziu •Using Functional Precision Medicine to Manage Cancer  - Diana Azzam
16:45 - 17:15	Session 2: Poster flash talks
	Chair: Caroline Heckman
	Nastassja Scheidegger; Luca Pagliaro; Philippe Rousselot; Weeda Mamoza; Jasmeet Sidhu; Pamela Becker
17:30 - 18:45	Session 3A:  Biomarkers/diagnostics with therapeutic impact	Session 3B:  Data Sharing/harmonization	Session 3C:  Addressing intra-patient heterogeneity in diagnosis, treatment and disease monitoring
	Chair: Konstanze Döhner	Chair: Aedin Culhane	Chair: Thorsten Zenz
	• Genetics guiding therapy in Acute Myeloid Leukemia - Konstanze Döhner • PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors - Sanju Sinha • Oral Abstract  - Nona Struyf	• Multi-omic data harmonization - Aedin Culhane • Data for the Common Good: Transforming health through data - Samuel Volchenboum • The Danish Lymphoid-lineage Cancer Research (DALY-CARE) resource – an example cohort of +65000 patients with +3000 routine data variables per patient for development of data-driven hematology - Carsten Niemann	• Modelling and targeting intra-patient heterogeneity in pediatric cancers - Kasper Karlsson • Targeting heterogeneity in CLL: Pathway connectivity resolved by drug perturbation and RNA sequencing - Thorsten Zenz • Oral Abstract - Jeremy Ariey-Bonnet
18:45 - 19:45	Welcome Reception + poster walk (Foyer)

Day 2: Thursday, September 26

 

	Vandsalen	Ballonsalen	Blomstersalen
08:30 - 09:45	Session 4: Next generation approaches to precision medicine
	Chair: Ina Oehme
	• Identifying precision apoptosis in solid and hematological cancers - Anthony Letai • The pediatric drug sensitivity profiling - Ina Oehme • Oral Abstract - Rita Fior
09:45 - 10:15	Session 5: Poster flash talks
	Chair: Caroline Heckman
	Romika Kumari; Alexander Pichler; Patrick Bhola; Josie Christopher; Albert Manzano-Muñoz; Sarah Unterberger
10:15 - 10:45	Coffee break (Foyer)
10:45 - 12:15	Session 6A: Trial design, n-of-1	Session 6B:  Technologies	Session 6C: Computational approaches to PM
	Chair: Philipp Staber	Chair: Joan Montero	Chair: Jing Tang
	• Trial design of precision medicine studies; n-of -1 and others - Philipp Staber Short presentations: • Trial design of MATCH: pros and cons - Keith Flaherty • Trial design of EVIDENT: pros and cons - Kushtrim Kryeziu • Trial design of EXALT-2: pros and cons - Lukas Kazianka • Panel discussion on future of diagnostic led trials	•Introduction - Joan Montero •Spatial profiling of the acute leukaemia microenvironment - Sergio Rutella •Organoid technologies for functional precision medicine - Alice Soragni •A data-driven approach to assess technologies for precision cancer medicine - Olli Kallioniemi •Single cell mass-based biomarkers for functional precision medicine - Keith Ligon •Panel discussion •Discussion with the audience and summary	•Introduction - Jing Tang •Panel discussion - Aedin Culhane; Jing Tang,Kasper Karlsson, Jesse Boehm, Sanju Sinha - The state-of-the-art of computational approaches - Computational complexity versus biological complexity - Interpretability and transferability of computational approaches - Challenges and benefits of federated versus centralized approaches - Implementation in the clinics
12:15 - 13:15	Lunch break (Foyer)
13:15 - 14:00	Keynote
	Introduction: Brian Huntly
	Elli Papaemmanuil
14:00 - 14:30	Session 7: Poster flash talks
	Chair:Caroline Heckman
	Anna Popova; Lucía Rico Pizarro; Sigrid S.Skånland; Breanna Mann; Caroline Stockwell; Philippe Rousselot
14:45 - 16:00	Session 8A: Precision medicine in the context of rare and ultra-rare tumors	Session 8B: Identification of combination therapies	Session 8C: Next-generation genomic precision medicine
	Chair: Beat Bornhauser	Chair: Anand Jeyasekharan	Chair: Ann-Kathrin Eisfeld
	•Precision medicine in childhood leukemia - Beat Bornhauser •Leveraging patient-derived organoids for rare cancer research: from basic research to clinical applications - Alice Soragni •Targeting apoptosis regulators to enhance natural killer cell-based immunotherapy in aggressive B cell lymphomas - Eva Szegezdi	•Patient-specific drug combinations in relapsed/ refractory lymphoma - Anand Jeyasekharan •From single cell analyses to effective drug combinations in solid and hematological cancers - Tero Aittokallio •Oral absract - Eva Daniela Mendoza Ortiz	•Genomic approaches to enable equitable care and precision medicine for patients with acute myeloid leukemia - Ann-Kathrin Eisfeld •Next gen genomic precision medicine in solid tumors - Jason Sicklick •Oral abstract - Athanasios Oikonomou
16:00 - 16:30	Coffee break (Foyer)
16:30 - 18:00	Session 9A: Regulatory: Approval processes, reimbursement, diagnostics	Session 9B: Visibility & education	Session 9C: Data management, sharing, tools, Data standardization
	Chair: Keith Ligon	Chair: Josef Vormoor	Chair: Caroline Heckman
	•Introduction - Keith Ligon •Panel discussion - Keith Ligon, Keith Flaherty, Sharon McWeeney, Philipp Staber - Research and early diagnostics development and planning for launch incorporation into clinical trials - Clinical trials and companion diagnostics with FDA experience in US and EU markets - Data science, AI/ML development, and regulatory management for use in clinical trials and diagnostics - Reimbursement pathways and experiences in public and private sectors for precision medicine •Discussion with the audience and summary	•Introduction: What is Precision Medicine - Josef Vormoor •Why there is a need for raising awareness & education - Konstanze Döhner •What do we need for educating HCPs? - Jean-Pierre Bourquin •How do we create public awareness? - Nicole Scobie •Panel discussion on How can we accelerate the implementation of precision therapy by raising public awareness and educating medical professionals? All panelists •Conclusion remarks & action points for audience	•Introduction: Caroline Heckman •Panel discussion - Tero Aittokallio, Pamela Becker, Kimmo Porkka, Alex Dahmani, and Caroline Heckman - Global data sharing: needs, challenges, opportunities (includes, legislation, differences in EU vs US vs other parts of the world) - Data-sharing models - Public repositories and publicly available data - Data standardization and analysis tools, integration for use •Discussion with the audience and summary

Day 3: Friday, September 27

	Vandsalen	Ballonsalen	Blomstersalen
09:00 - 10:30	Session 10A:  How should a tumor board operate? How to ensure patient access and patient centricity?	Session 10B: Optimizing specimen handling for precision medicine applications
	Chair: Jean-Pierre Bourquin and Nicole Scobie	Chair: Tea Pemovska
	•Questions raised from current practice - Jean-Pierre Bourquin •Issues about access, bottlenecks, and the patient perspective - Nicole Scobie Part I “Validation of novel decision-making tools to be used in tumor boarAccess to precision medicines • Structure of tumor board and biological reporting: example of ATTRACT - Ludovic Lhermitte • Assay Certification and Investigational Device Exemption for clinical trials - Kristine Crews & Antonhy Letai Q&A from the Audience Part II "Access to precision medicine" •The patient advocate perspective  - Karin Holm Part III “Leveraging Artificial Intelligence and Data Science n Clinical Decision-Making: Optimizing Input and Output for Precision Medicine? • Utility of anonymized and synthetic data - Kimmo Porkka • AI to support board preparation and reporting - Uri Ilan & Fabio Steffen •Panel discussion	•Introduction - Tea Pemovska •Best practices for specimen shipping, storage, and quality control samples handling including guidelines - Tea Pemovska •EXALT study real-life example practices for blood, bone marrow, and lymph node specimen handling - Tea Pemovska •Panel discussion on best practices of specimen handling for precision medicine applications of solid tissues - Tea Pemovska & Alice Soragni •Discussion with audience and summary
10:30 - 11:00	Coffee break
11:00 - 12:15	Session 11A: Immunotherapy - predicting responses	Session 11B: Models for functional precision medicine	Session 11C: Measurable residual disease monitoring
	Chair: Sergio Rutella	Chair: Clare Scott	Chair: Monika Brüggemann
	•Patient-derived non-Hodgkin lymphoma tumoroids: A tool for precision medicine - Patricia Perez-Galan •Predicting responses to immunotherapies in acute myeloid leukaemia - Sergio Rutella •Oral abstract - Zakhar Krekhno	•Using organoid models to guide therapy - Calvin Kuo •Therapeutic response and resistance informed by preclinical models of rare gynaecological cancers - Clare Scott •Oral abstract - Andrew Satterlee	•MRD in acute leukemias – how and why? - Monika Brüggemann •Oral abstract - Emma Frasez Sørensen
12:15 - 13:15	Lunch break (foyer)
13:15 - 14:30	Session 12: AI for precision medicine
	Chair: Shannon McWeeney
	•AI in genomic analyses of hematological cancers - Shannon McWeeney •Rapid ex vivo biosensor cultures to assess dependencies in gastroesophageal cancer​ - Jesse Boehm •Oral abstract - Landon Choi
14:30 - 15:15	Keynote: Technology- and data-driven precision medicine in the AI era
	Introduction: Anthony Letai
	Olli Kallioniemi
15:15 - 15:30	Closing
	Joan Montero